World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
115
Citations
77405
World Ranking
4431
National Ranking
2414

Overview

Joaquim Bellmunt is affiliated with the Beth Israel Deaconess Medical Center in the United States. Their research primarily focuses on medicine, with extensive work in surgery, oncology, pulmonary and respiratory medicine, molecular biology, and cancer research.

The scientist's main topics of research include bladder and urothelial cancer treatments, urinary and genital oncology studies, cancer immunotherapy and biomarkers, esophageal cancer research and treatment, renal cell carcinoma treatment, prostate cancer treatment and research, and multiple and secondary primary cancers.

Joaquim Bellmunt has published research in several frequent venues, including:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • The Journal of Urology
  • European Urology
  • Urologic Oncology Seminars and Original Investigations

Recent papers featuring Bellmunt's authorship cover a range of advanced topics in urothelial carcinoma and immunotherapy. These include:

  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma, 2020, New England Journal of Medicine
  • ctDNA guiding adjuvant immunotherapy in urothelial carcinoma, 2021, Nature
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, 2020, The Lancet Oncology
  • Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial, 2021, The Lancet Oncology

Frequent coauthors collaborating with Bellmunt include:

  • Petros Grivas
  • Thomas Powles
  • Srikala S. Sridhar
  • Shilpa Gupta
  • Yohann Loriot

Best Publications

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Erik Briers

  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet

  • EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

    Axel Heidenreich;Patrick J. Bastian;Joaquim Bellmunt;Michel Bolla

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

    A. Gordon Robertson;Jaegil Kim;Hikmat Al-Ahmadie;Joaquim Bellmunt

  • EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

    Axel Heidenreich;Joaquim Bellmunt;Michel Bolla;Steven Joniau

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

    Philip Cornford;Joaquim Bellmunt;Michel Bolla;Erik Briers

  • EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer ☆

    Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Steven Joniau

  • First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

    Arjun V Balar;Daniel Castellano;Peter H O'Donnell;Petros Grivas

  • 前立腺癌のEAUガイドライン。パート1:臨床的限局性疾患のスクリーニング,診断および治療

    A Heidenreich;J Bellmunt;M Bolla;S Joniau

  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    Thomas Powles;Se Hoon Park;Eric Voog;Claudia Caserta

  • Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

    Bernard Escudier;Joaquim Bellmunt;Sylvie Négrier;Emilio Bajetta

  • A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

    Aurélie Kamoun;Aurélien de Reyniès;Yves Allory;Yves Allory;Gottfrid Sjödahl

  • Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

    Joaquim Bellmunt;Christine Théodore;Tomasz Demkov;Boris Komyakov

  • Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

    P Dombernowsky;I Smith;G Falkson;R Leonard

  • Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

    Maria De Santis;Joaquim Bellmunt;Graham Mead;J. Martijn Kerst

  • Guidelines on Prostate Cancer

    A. Heidenreich;J. Bellmunt;M. Bolla;S. Joniau

  • EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer - Guía de la EAU sobre el cáncer de próstata. Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración

    N. Mottet;J. Bellmunt;M. Bolla;S. Joniau

Frequent Co-Authors

Toni K. Choueiri
Toni K. Choueiri Harvard University
Jonathan E. Rosenberg
Jonathan E. Rosenberg Memorial Sloan Kettering Cancer Center
Thomas Powles
Thomas Powles Queen Mary University of London
Cora N. Sternberg
Cora N. Sternberg Cornell University
Dean F. Bajorin
Dean F. Bajorin Memorial Sloan Kettering Cancer Center
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Elizabeth R. Plimack
Elizabeth R. Plimack Fox Chase Cancer Center
Eliezer M. Van Allen
Eliezer M. Van Allen Harvard University
Gregory R. Pond
Gregory R. Pond McMaster University
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Medicine but seeking alternative or complementary career options, there are a variety of affordable online degrees to consider. Those aiming to become pharmacists can explore 3 year online pharmd programs, offering a flexible route to advanced pharmacy credentials.

If you are interested in the intersection of healthcare and technology, health information technology programs online provide training in data management, security, and analysis, which are essential skills in today’s medical landscape.

Another growing field is medical billing and coding, where you can earn certifications without breaking the bank. Learn more about medical coding certification cost and find cost-effective pathways to enter this essential healthcare role.

For those pursuing advanced practice in nursing, there are options for high-quality education at lower costs. Discover the cheapest online nurse practitioner programs and earn credentials that open up diverse patient care opportunities.

These online programs offer flexible solutions for building a successful career in healthcare—whether your passion is clinical work, technology, administration, or beyond.

Best Scientists Citing Joaquim Bellmunt

Trending Scientists